Team:Panama

ABSTRACT

Rhamnolipids are naturally occurring glycolipids produced by the Pseudomonas aeruginosa. Rhamnolipids have many applications, because of their natural biosurfactant, emulsifying, fungicidal, antibiotic, and pharmaceutical properties. Also rhamnolipids can operate in extreme conditions such as high temperature, pH, and salinity. They have a low toxicity, and they are biodegradable compared to their synthetic chemical counterparts. Rhamnolipid is composed of rhamnose sugar molecule and b-hydroxyalkanoic acid. The rhamnosyltransferase 1 complex (RhlAB) is the key enzyme responsible for transferring the rhamnose moiety to the b-hydroxyalkanoic acid moiety to biosynthesize rhamnolipid. Since the organisms known to produce rhamnolipids are almost exclusively pathogens. For this reason, we propose the non-pathogenic nature of E. coli as an attractive candidate for commercial rhamnolipid production by assembling our rhamnosyltransferase 1 gene (rhlAB) into a BioBrick using synthetic biology to engineer these new rhamnosyltransferase 1 producing bacteria for human benefit.

Our aim is to construct a BioBrick that leads to the production of rhamnosyltransferase 1 enzyme in E.coli, it will not be easy because the natural gene sequence of rhamnosyltransferase 1 complex (RhlAB) include illegal restriction sites and requires modifications to be fit into a BioBrick. The solution to this problem could be solved, by performing silent mutations in the gene sequence. To prove our goal we will do bio-assays with our new E. coli rhlAB strain to degrade rhamnose sugars and fatty-acids substrates and turn it in rhamnolipids. We hope that our BioBricks will become a useful tool for the bioengineered industry and widely used as a simple and effective means of rhamnolipid production.